Kanuma (Intravenous) Uses, Dosage, Side Effects and more
Kanuma (Intravenous) Uses, Dosage, Side Effects, Food Interaction and all others data.
Kanuma (Intravenous) is a recombinant form of the enzyme lysosomal acid lipase (LAL) approved for the treatment of lysosomal acid lipase deficiency (LAL-D). The amino acid sequence for sebelipase alfa is the same as the amino acid sequence for human LAL. Kanuma (Intravenous) is an orphan drug which is expected to cost about $310,000 for annual treatment in the United States. Kanuma (Intravenous) is marketed under the brand name Kanuma™ by Alexion Pharmaceuticals, Inc.
| Trade Name | Kanuma (Intravenous) |
| Generic | Sebelipase alfa |
| Sebelipase alfa Other Names | SBC-102, Sebelipasa alfa, Sebelipase alfa |
| Type | |
| Formula | C1968H2945N507O551S15 |
| Weight | 55000.0 Da |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | USA |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Kanuma (Intravenous) is a recombinant lysosomal acid lipase used to treat lysosomal acid lipase deficiency.
Kanuma (Intravenous) is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.
Kanuma (Intravenous) is also used to associated treatment for these conditions: Lysosomal Acid Lipase Deficiency
How Kanuma (Intravenous) works
LAL deficiency is an autosomal recessive lysosomal storage disorder characterized by a genetic defect resulting in a marked decrease or loss in activity of the lysosomal acid lipase (LAL) enzyme. The primary site of action of the LAL enzyme is the lysosome, where the enzyme normally causes the breakdown of lipid particles including LDL-c. Deficient LAL enzyme activity results in progressive complications due to the lysosomal accumulation of cholesteryl esters and triglycerides in multiple organs, including the liver, spleen, intestine, and the walls of blood vessels. The resulting lipid accumulation in the liver may lead to increased liver fat content and progression of liver disease, including fibrosis and cirrhosis. Lipid accumulation in the intestinal wall leads to malabsorption and growth failure. In parallel, dyslipidemia due to impaired degradation of lysosomal lipid is common with elevated LDL-c and triglycerides and low HDL-cholesterol (HDL-c). Kanuma (Intravenous) binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. Kanuma (Intravenous) catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol and free fatty acids.
